Not logged in An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors Mukker, Jatinder Kaur; Yap, Timothy A.; Tolcher, Anthony W.; de Bono, Johann S.; Plummer, Ruth; Grosser, Gary; van Amsterdam, Christoph; Schieferstein, Hanno; Witjes, Han; Diderichsen, Paul Matthias; Krebs-Brown, Axel; Gao, Wei; Strotmann, Rainer; Szucs, Zoltan; Gounaris, Ioannis; Venkatakrishnan, Karthik Share Save
Share Save
Share Save
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors (vol 14, 1376551, 2024) Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; Lorusso, Patricia; Miller, Kathy D.; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; Blaney, Martha; Leibman, Rachel; Golan, Talia; Tolcher, Anthony Share Save
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; Lorusso, Patricia; Miller, Kathy D.; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; Blaney, Martha; Leibman, Rachel; Golan, Talia; Tolcher, Anthony Share Save
Share Save
Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC) Park, W.; Kasi, A.; Spira, A. I.; Berlin, J. D.; Wang, J. S.; Herzberg, B.; Kuboki, Y.; Kitano, S.; Pelster, M.; Goldman, J. W.; Morgensztern, D.; Kondo, S.; Janne, P. A.; Fujii, H.; Lee, H-J.; Gill, S.; Saci, A.; Lorusso, P.; Tolcher, A. W. Share Save
Translational, PK, PD, and immunophenotyping analyses of tuvusertib plus niraparib in a phase Ib open-label multicenter dose-escalation study in patients with advanced solid tumors (DDRiver Solid Tumors 301) Tolcher, A. W.; Yap, T. A.; Plummer, R.; Sommerhalder, D.; Rodon, J.; Lagonera, M.; Bergmann, P.; Perez, V. Sanchez; Wohlfeil, N.; Wang, D.; Mukker, J. Kaur; Sessa, G.; Manginelli, A.; de Bono, J. S. Share Save
Share Save
A Phase I/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors Janjigian, Yelena; Tolcher, Anthony; Mehta, Rutika; Cecchini, Michael; Van Tine, Brian; Kundranda, Madappa; Olatunji, Alese; Patel, Manish R.; Berlin, Jordan; Rocha-Lima, Caio Max Sao Pedro; Monga, Dulabh; Ben George; Scott, Aaron; Xia, Zhenzhong; Elsafy, Mohamed; Jones, Erikca; Yao, Zhenling; Qi, Chuan; Germa, Caroline; Gabrail, Nash Share Save
First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer Bazhenova, Lyudmila; Mamdani, Hirva; Chiappori, Alberto; Spira, Alexander; Iams, Wade; Tolcher, Anthony; Barve, Minal; Gabayan, Afshin; Vandross, Andrae; Cina, Cima; Cohen-Arazi, Yael; Albaugh, Zachary; Huynh, Annie; Gullbo, Joachim; Zabludoff, Sonya Share Save
First-in-human trial of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with advanced solid unresectable tumors Naing, Aung; McKean, Meredith; Tolcher, Anthony; Victor, Anja; Hu, Ping; Mehr, Keyvan Tadjalli; Kitzing, Thomas; Holland, Daniel; Richter, Emilia; Siu, Lillian Share Save
Phase Ib trial of ATR inhibitor (ATRi) tuvusertib plus ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors Siu, Lillian L.; Cabanas, Elena Garralda; Boni, Valentina; Tolcher, Anthony W.; Garcia, Enrique Sanz; Fuentes-Antras, Jesus; Saavedra, Omar; Vagge, Deepthi S.; Locatelli, Giuseppe; Gunhan, Burak Kursad; Pennock, Gregory; Mukker, Jatinder Kaur; Gounaris, Ioannis; Yap, Timothy A. Share Save
Share Save
Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53 Dumbrava, Ecaterina E.; Iwamoto, Fabio M.; Agulnik, Mark; Milhem, Mohammed; Tolcher, Anthony W.; Chugh, Rashmi; Demeure, Michael J.; Mita, Alain; Demel, Kurt; Diamond, Mark; Mirakhur, Beloo; Wilson, Laksmi; Oganesian, Aram; Chan, Danna; Keer, Harold N.; Taylor, Jason; Sims, Martin J.; Biondo, Andrea; Jueliger, Simone; Spira, Alexander Share Save
Pharmacokinetic/biomarker (PK/ BMx) analysis of the toll- like receptor 7 and 8 (TLR7/8) agonist EIK1001 in phase 1 studies in participants (Pts) with solid tumors Rasco, Drew; Patel, Manish; Johnson, Melissa; Tolcher, Anthony; Sommerhalder, David; Hamid, Omid; Alistar, Angela; Kochan, Jarema; Kurland, Etah; Wang, Meihua; Cho, Carolyn; Rebello, Sam Share Save
Share Save
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors Yap, Timothy A.; Tolcher, Anthony W.; Plummer, Ruth; Mukker, Jatinder Kaur; Enderlin, Marta; Hicking, Christine; Grombacher, Thomas; Locatelli, Giuseppe; Szucs, Zoltan; Gounaris, Ioannis; de Bono, Johann S. Share Save
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors Tolcher, Anthony W.; Brody, Joshua D.; Rajakumaraswamy, Nishanthan; Kuhne, Michelle; Trowe, Torsten; Dauki, Anees M.; Pai, Shantheri; Han, Ling; Lin, Kai-Wen; Petrarca, Michael; Kummar, Shivaani Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}